{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:34:18Z","timestamp":1793658858167,"version":"4.5.1"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"The SNUH Research","award":["03-2017-0100"],"award-info":[{"award-number":["03-2017-0100"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.pharmthera.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:12:45Z","timestamp":1562670765000},"page":"107391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":225,"special_numbering":"C","title":["ATM in DNA repair in cancer"],"prefix":"10.1016","volume":"203","author":[{"given":"Mei Hua","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.07.002_bb0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.freeradbiomed.2016.11.039","article-title":"Coordination of DNA single strand break repair","volume":"107","author":"Abbotts","year":"2017","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0010","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.celrep.2016.07.038","article-title":"NOTCH1 inhibits activation of ATM by impairing the formation of an ATM-FOXO3a-KAT5\/Tip60 complex","volume":"16","author":"Adamowicz","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/pai.13020","article-title":"Ataxia-telangiectasia: A review of clinical features and molecular pathology","volume":"30","author":"Amirifar","year":"2019","journal-title":"Pediatric Allergy and Immunology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0020","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1544442","article-title":"PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer","volume":"8","author":"Angell","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0025","first-page":"4255","article-title":"ATM and ATR signaling at a glance","volume":"128","author":"Awasthi","year":"2015","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0030","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/15384101.2017.1312236","article-title":"Susceptibility of ATM-deficient pancreatic cancer cells to radiation","volume":"16","author":"Ayars","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1700933","article-title":"Structures of closed and open conformations of dimeric human ATM","volume":"3","author":"Baretic","year":"2017","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0040","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2613.2010.00734.x","article-title":"STAT3 modulates the DNA damage response pathway","volume":"91","author":"Barry","year":"2010","journal-title":"International Journal of Experimental Pathology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0045","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1535-7163.MCT-12-0707","article-title":"Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer","volume":"12","author":"Batey","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41577-019-0135-6","article-title":"At the intersection of DNA damage and immune responses","volume":"19","author":"Bednarski","year":"2019","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0055","first-page":"3003","article-title":"Promoter Hypermethylation of the ATM gene as a novel biomarker for breast cancer","volume":"18","author":"Begam","year":"2017","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41594-018-0075-z","article-title":"RPA and RAD51: Fork reversal, fork protection, and genome stability","volume":"25","author":"Bhat","year":"2018","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0065","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-12-3408","article-title":"ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation","volume":"19","author":"Biddlestone-Thorpe","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0075","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.oraloncology.2005.06.003","article-title":"The ATM\/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms","volume":"41","author":"Bolt","year":"2005","journal-title":"Oral Oncology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0080","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.celrep.2013.06.039","article-title":"Functional activation of ATM by the prostate cancer suppressor NKX3.1","volume":"4","author":"Bowen","year":"2013","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0085","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm2351","article-title":"Regulation of DNA repair throughout the cell cycle","volume":"9","author":"Branzei","year":"2008","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0090","article-title":"The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression","volume":"7","author":"Buglioni","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0095","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.cell.2015.08.006","article-title":"Not all DDRs are created equal: Non-canonical DNA damage responses","volume":"162","author":"Burgess","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2017.08.013","article-title":"DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy","volume":"60","author":"Carrassa","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0105","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2014.08.003","article-title":"Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase","volume":"9","author":"Carruthers","year":"2015","journal-title":"Molecular Oncology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","article-title":"Repair pathway choices and consequences at the double-strand break","volume":"26","author":"Ceccaldi","year":"2016","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.it.2014.06.003","article-title":"DNA damage and innate immunity: Links and trade-offs","volume":"35","author":"Chatzinikolaou","year":"2014","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","article-title":"Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and Cancer","volume":"2","author":"Chen","year":"2018","journal-title":"Annual Review Cancer Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0130","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/1440-1681.12745","article-title":"INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells","volume":"44","author":"Chen","year":"2017","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0135","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.07270","article-title":"ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion","volume":"4","author":"Chen","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0140","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in Cancer: Therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0145","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1038\/onc.2013.275","article-title":"ATM signalling and cancer","volume":"33","author":"Cremona","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0150","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","article-title":"DNA repair targeted therapy: The past or future of cancer treatment?","volume":"160","author":"Gavande","year":"2016","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1756-9966-32-95","article-title":"ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition","volume":"32","author":"Gilardini Montani","year":"2013","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0170","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","article-title":"Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion","volume":"8","author":"Golding","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2015.12.009","article-title":"ATM kinase: Much more than a DNA damage responsive protein","volume":"39","author":"Guleria","year":"2016","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0180","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/onc.2015.361","article-title":"INPP4B is an oncogenic regulator in human colon cancer","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0185","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41467-019-09641-9","article-title":"Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks","volume":"10","author":"Ha","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fonc.2017.00098","article-title":"Targeting ongoing DNA damage in multiple myeloma: Effects of DNA damage response inhibitors on plasma cell survival","volume":"7","author":"Herrero","year":"2017","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0200","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0205","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cas.12366","article-title":"Targeting DNA damage response in cancer therapy","volume":"105","author":"Hosoya","year":"2014","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0210","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0215","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/cr.2017.36","article-title":"Baf60b-mediated ATM-p53 activation blocks cell identity conversion by sensing chromatin opening","volume":"27","author":"Ji","year":"2017","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0220","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.celrep.2018.06.089","article-title":"Homeodomain proteins directly regulate ATM kinase activity","volume":"24","author":"Johnson","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0225","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41416-018-0286-4","article-title":"PRAD50: A novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry","volume":"119","author":"Jones","year":"2018","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0230","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1038\/onc.2015.427","article-title":"RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress","volume":"35","author":"Kanu","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0235","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-17-0975","article-title":"Orally bioavailable and blood-brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice","volume":"17","author":"Karlin","year":"2018","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0240","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","article-title":"CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis","volume":"24","author":"Katoh","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0245","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-13-1239","article-title":"Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis","volume":"20","author":"Kim","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000346034","article-title":"Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients","volume":"80","author":"Kim","year":"2013","journal-title":"Pathobiology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0255","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ijc.28245","article-title":"Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker","volume":"134","author":"Kim","year":"2014","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0260","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1073\/pnas.1400683111","article-title":"STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation","volume":"111","author":"Koganti","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0265","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(03)00719-0","article-title":"Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks","volume":"114","author":"Konishi","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0270","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1074\/jbc.M110.204065","article-title":"Autophosphorylation and ATM activation: Additional sites add to the complexity","volume":"286","author":"Kozlov","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0275","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1073\/pnas.131009198","article-title":"Single-strand interruptions in replicating chromosomes cause double-strand breaks","volume":"98","author":"Kuzminov","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0280","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/15384101.2016.1158362","article-title":"Structure of the human dimeric ATM kinase","volume":"15","author":"Lau","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0285","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.3390\/biom5042877","article-title":"ATM-dependent phosphorylation of all three members of the MRN complex: From sensor to adaptor","volume":"5","author":"Lavin","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0290","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/bjc.2012.177","article-title":"Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis","volume":"106","author":"Lee","year":"2012","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0295","doi-asserted-by":"crossref","first-page":"21698","DOI":"10.1038\/srep21698","article-title":"Mechanisms and consequences of ATMIN repression in hypoxic conditions: Roles for p53 and HIF-1","volume":"6","author":"Leszczynska","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0300","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.celrep.2019.01.013","article-title":"PPARgamma interaction with UBR5\/ATMIN promotes DNA repair to maintain endothelial homeostasis","volume":"26","author":"Li","year":"2019","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0305","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yexcr.2018.03.006","article-title":"ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin","volume":"366","author":"Li","year":"2018","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0310","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41422-018-0048-0","article-title":"Destabilization of linker histone H1.2 is essential for ATM activation and DNA damage repair","volume":"28","author":"Li","year":"2018","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.dnarep.2017.06.022","article-title":"ASCIZ\/ATMIN is dispensable for ATM signaling in response to replication stress","volume":"57","author":"Liu","year":"2017","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2016.12.040","article-title":"The depletion of ATM inhibits colon cancer proliferation and migration via B56gamma2-mediated Chk1\/p53\/CD44 cascades","volume":"390","author":"Liu","year":"2017","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0325","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/2159-8290.CD-17-0267","article-title":"TOX regulates growth, DNA repair, and genomic instability in T-cell acute lymphoblastic leukemia","volume":"7","author":"Lobbardi","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0330","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0335","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccell.2019.01.020","article-title":"Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair","volume":"35","author":"Ma","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0340","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41467-018-05228-y","article-title":"The therapeutic significance of mutational signatures from DNA repair deficiency in cancer","volume":"9","author":"Ma","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0345","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.gde.2013.05.007","article-title":"Break-induced replication: Functions and molecular mechanism","volume":"23","author":"Malkova","year":"2013","journal-title":"Current Opinion in Genetics & Development"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0350","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1038\/s41598-018-22289-7","article-title":"Loss of PTEN-assisted G2\/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer","volume":"8","author":"Mansour","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0355","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00018-016-2130-4","article-title":"The DNA damage-induced cell death response: A roadmap to kill cancer cells","volume":"73","author":"Matt","year":"2016","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0360","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-14-3502","article-title":"Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM","volume":"75","author":"McCabe","year":"2015","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0365","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12035-014-8864-9","article-title":"Linking ATM promoter methylation to cell cycle protein expression in brain tumor patients: Cellular molecular triangle correlation in ATM territory","volume":"52","author":"Mehdipour","year":"2015","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0370","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, A novel Oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad8243","article-title":"Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML","volume":"9","author":"Morgado-Palacin","year":"2016","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-019-0305-x","article-title":"ING3 is required for ATM signaling and DNA repair in response to DNA double strand breaks","author":"Mouche","year":"2019","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0385","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA damage and repair biomarkers of immunotherapy response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0390","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor","year":"2015","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0395","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: Origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0400","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1038\/onc.2011.21","article-title":"HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents","volume":"30","author":"Palmieri","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0405","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrc3891","article-title":"Therapeutic opportunities within the DNA damage response","volume":"15","author":"Pearl","year":"2015","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0410","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-17-0634","article-title":"ATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damage","volume":"77","author":"Perkhofer","year":"2017","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0415","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"Pike","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0420","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0425","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41467-019-09175-0","article-title":"UFL1 promotes histone H4 ufmylation and ATM activation","volume":"10","author":"Qin","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0430","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-0763","article-title":"Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation","volume":"68","author":"Rainey","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0435","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","article-title":"Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes","volume":"8","author":"Riaz","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0440","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0445","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1016\/j.celrep.2016.12.003","article-title":"RPA stabilization of single-stranded DNA is critical for break-induced replication","volume":"17","author":"Ruff","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0450","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-04-2378","article-title":"Methylation profiling of archived non-small cell lung cancer: A promising prognostic system","volume":"11","author":"Safar","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0455","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pharmthera.2016.02.007","article-title":"Cancer TARGETases: DSB repair as a pharmacological target","volume":"161","author":"Samadder","year":"2016","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0460","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature06337","article-title":"Human ctip promotes DNA end resection","volume":"450","author":"Sartori","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0465","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0470","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.dnarep.2014.09.001","article-title":"ATMIN is required for the ATM-mediated signaling and recruitment of 53BP1 to DNA damage sites upon replication stress","volume":"24","author":"Schmidt","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0475","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM deficiency is associated with sensitivity to PARP1- and ATR inhibitors in lung adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0480","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","article-title":"Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway","volume":"38","author":"Shen","year":"2019","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0485","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors--moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0490","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/sj.emboj.7601446","article-title":"ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling","volume":"25","author":"Stiff","year":"2006","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0495","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fgene.2013.00037","article-title":"The ATM signaling network in development and disease","volume":"4","author":"Stracker","year":"2013","journal-title":"Frontiers in Genetics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0500","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10549-016-3869-x","article-title":"Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer","volume":"158","author":"Suh","year":"2016","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0505","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc3344","article-title":"Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer","volume":"12","author":"Sulli","year":"2012","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0510","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1073\/pnas.0504211102","article-title":"A role for the tip60 histone acetyltransferase in the acetylation and activation of ATM","volume":"102","author":"Sun","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0515","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1128\/MCB.01382-07","article-title":"DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity","volume":"27","author":"Sun","year":"2007","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0520","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav1118","article-title":"SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA damage repair","volume":"5","author":"Tang","year":"2019","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0525","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1535-7163.MCT-12-1242","article-title":"Histone deacetylase regulation of ATM-mediated DNA damage signaling","volume":"12","author":"Thurn","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0530","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nsmb.3013","article-title":"Notch is a direct negative regulator of the DNA-damage response","volume":"22","author":"Vermezovic","year":"2015","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0535","doi-asserted-by":"crossref","first-page":"9432","DOI":"10.1038\/sj.onc.1208092","article-title":"The ATM gene is a target for epigenetic silencing in locally advanced breast cancer","volume":"23","author":"Vo","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0540","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-deficient colorectal Cancer cells are sensitive to the PARP inhibitor olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Translational Oncology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0545","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/onc.2015.228","article-title":"A central role of TRAX in the ATM-mediated DNA repair","volume":"35","author":"Wang","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0550","doi-asserted-by":"crossref","first-page":"12513","DOI":"10.1007\/s13277-016-5111-1","article-title":"INPP4B-mediated DNA repair pathway confers resistance to chemotherapy in acute myeloid leukemia","volume":"37","author":"Wang","year":"2016","journal-title":"Tumour Biology"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0555","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/nar\/gkz110","article-title":"MRE11 UFMylation promotes ATM activation","volume":"47","author":"Wang","year":"2019","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0560","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0565","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0570","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.dnarep.2014.02.011","article-title":"The clinical impact of deficiency in DNA non-homologous end-joining","volume":"16","author":"Woodbine","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0575","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.molcel.2012.02.018","article-title":"Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1","volume":"46","author":"Wu","year":"2012","journal-title":"Molecular Cell"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0580","doi-asserted-by":"crossref","first-page":"11642","DOI":"10.1002\/jcb.28444","article-title":"Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway","volume":"120","author":"Zhang","year":"2019","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0585","doi-asserted-by":"crossref","first-page":"12091","DOI":"10.1073\/pnas.1400230111","article-title":"UBR5-mediated ubiquitination of ATMIN is required for ionizing radiation-induced ATM signaling and function","volume":"111","author":"Zhang","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.07.002_bb0590","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3109\/09553002.2015.1001531","article-title":"The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect","volume":"91","author":"Zhang","year":"2015","journal-title":"International Journal of Radiation Biology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:03:12Z","timestamp":1759010592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819301287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":118,"alternative-id":["S0163725819301287"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.07.002","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATM in DNA repair in cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107391"}}